DDInter1668 DDInter875
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propafenone
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Propafenone
Siltuximab may lead to a major life threatening interaction when taken with Etanercept
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib